Studies have shown that Nrf2 has many activities, including antioxidant, anti-inflammatory, modulation of heme, regulation of iron metabolism, and detoxification of xenobiotics. Some inducers of Nrf2 such as tert-butylhydroquinone, dimethyl fumarate, or activators such as sulforaphane have also been found to be effective in restoring the neuroprotective effects of ischemic stroke injury. Therefore, targeting Nrf2 for stroke drug development is a potential avenue for stroke treatment. In view of this, Ace Therapeutics offers excellent services to develop stroke drugs targeting Nrf2.
The current studies suggest that the direction of targeting Nrf2 for stroke is mainly Nrf2 inducers and activators. Therefore, the main focus of Ace Therapeutics in developing stroke drugs for Nrf2 is on inducers and activators of Nrf2. Based on our ultra-large small molecule library and different drug screening platforms, we perform extensive screening of Nrf2 inducers and activators to improve the success rate of obtaining potential modulators.
After confirming the activity of inducers and activators of Nrf2, along with preliminary validation to obtain drug candidates, for the drug candidates obtained from the screening, Ace Therapeutics conducts a more in-depth study to elucidate their specific mechanisms of action and efficacy in stroke treatment.
At the same time, we can tailor our research services exclusively to your research needs. If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.